infliximab biosimilars
Selected indexed studies
- The Experience with Biosimilars of Infliximab in Rheumatic Diseases. (Curr Pharm Des, 2017) [PMID:29189135]
- Infliximab Biosimilars in the Age of Personalized Medicine. (Trends Biotechnol, 2018) [PMID:29861288]
- Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. (BioDrugs, 2017) [PMID:28035633]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch? (2020) pubmed
- The Experience with Biosimilars of Infliximab in Rheumatic Diseases. (2017) pubmed
- Infliximab Biosimilars in the Age of Personalized Medicine. (2018) pubmed
- Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. (2017) pubmed
- The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. (2017) pubmed
- Progress with infliximab biosimilars for inflammatory bowel disease. (2018) pubmed
- Infliximab or biosimilars in sarcoidosis; to switch or not to switch? (2016) pubmed
- Biosimilars in rheumatology. (2019) pubmed
- The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences. (2021) pubmed
- Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. (2020) pubmed